Get notified of page updates

Search Results: Prevention, Detection & Risk (6 results)

PRINTER FRIENDLY PAGE 1 through 6 of 6
Screening Study for Pancreatic Cancer in People with Inherited Mutations

Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations

Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations

This study will look at how often routine MRI scans detect abnormal findings in people with inherited mutations in BRCA1, BRCA2, ATM, and PALB2, who are undergoing pancreatic cancer screening. Researchers want to learn how often MRI and endoscopic ultrasound (EUS) yield abnormal results, and how frequently they find pancreatic cancer or precancer. The study will also review the rate of procedures like biopsies and surgeries among participants. 

Clinicaltrials.gov identifier: NCT05058846
More info
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Prevention
Screening study for people with a mutation linked to prostate cancer risk

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

Clinicaltrials.gov identifier: NCT04472338
More info
Screening Study for Men at High Genetic Risk for Prostate Cancer

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Screening Study for Men at High Genetic Risk for Prostate Cancer

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

Clinicaltrials.gov identifier: NCT03805919
More info
Screening in Men at High Risk of Developing Prostate Cancer

Prevention
Screening using MRI for men at risk of developing prostate cancer

MRI Screening in Men at High Risk of Developing Prostate Cancer

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

Clinicaltrials.gov identifier: NCT05608694
More info
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. The study is enrolling people with an inherited mutation with a gene linked to ovarian cancer, such as BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.

More info
Pancreatic Cancer Screening Study for High Risk People

Prevention
Screening study to detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk

A Pancreatic Cancer Screening Study for High Risk Individuals

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

Clinicaltrials.gov identifier: NCT03250078
More info